2018 Clinical Development Immune Response Vaccine 
Drug Target Review
DECEMBER 28, 2023
These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response. To fell the entire tree, it is necessary to target the original clonal neoantigens that are present in every cancer cell.
The Pharma Data
DECEMBER 3, 2020
The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 11, 2021
Clinical trial to assess safety, immune response and reactogenicity, after preclinical data showed high neutralizing antibody levels. The joint development team is working on improving the temperature stability of the mRNA vaccine candidate and targeting a -20°C storage temperature for late-stage clinical trials and at launch.
The Pharma Data
JANUARY 31, 2021
Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. The candidate vaccines were given in two doses, three weeks apart. CHENGDU, China , Feb. CHENGDU, China , Feb.
The Pharma Data
OCTOBER 14, 2020
Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. 2018) PLoS One. Results from the PRECISION Study Expected in First Half of 2021. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.
Drug Discovery World
MAY 30, 2023
Combining multiple ICIs has shown improved efficacy, exemplified by the approval of Nivolumab plus Ipilimumab combination in MSI-high colorectal cancer in 2018. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed.
Drug Discovery World
FEBRUARY 15, 2023
Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was 375,400, with 167,142 deaths caused by cancer between 2017 and 2019. A brief history of vaccines and vaccination.
Expert insights. Personalized for you.
105 
Let's personalize your content